See more : Enjoy Technology, Inc. (ENJYW) Income Statement Analysis – Financial Results
Complete financial analysis of Miromatrix Medical Inc. (MIRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Miromatrix Medical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chugoku Marine Paints, Ltd. (4617.T) Income Statement Analysis – Financial Results
- Zeda Limited (ZZD.JO) Income Statement Analysis – Financial Results
- TKD Science and Technology Co.,Ltd. (603738.SS) Income Statement Analysis – Financial Results
- Aeva Technologies, Inc. Redeema (AEVA-WT) Income Statement Analysis – Financial Results
- VPN Technologies Inc. (VPN.CN) Income Statement Analysis – Financial Results
Miromatrix Medical Inc. (MIRO)
About Miromatrix Medical Inc.
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 953.47K | 33.07K | 46.53K | 250.00K |
| Cost of Revenue | 500.00K | 500.00K | 500.00K | 250.00K |
| Gross Profit | 453.47K | -466.93K | -453.47K | 0.00 |
| Gross Profit Ratio | 47.56% | -1,412.13% | -974.58% | 0.00% |
| Research & Development | 18.30M | 10.75M | 7.28M | 6.27M |
| General & Administrative | 8.72M | 4.64M | 2.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.72M | 4.64M | 2.11M | 2.44M |
| Other Expenses | 3.68M | 705.59K | -577.06K | -142.86K |
| Operating Expenses | 30.70M | 16.10M | 8.81M | 8.56M |
| Cost & Expenses | 31.20M | 16.60M | 9.31M | 8.81M |
| Interest Income | 333.47K | 1.97K | 8.73K | 106.43K |
| Interest Expense | 47.73K | 676.52K | 765.17K | 48.39K |
| Depreciation & Amortization | 333.47K | 171.37K | -1.19M | -142.56K |
| EBITDA | -29.91M | -16.79M | -11.45M | -9.13M |
| EBITDA Ratio | -3,137.20% | -50,771.66% | -24,598.53% | -3,653.69% |
| Operating Income | -30.25M | -16.96M | -10.26M | -8.99M |
| Operating Income Ratio | -3,172.17% | -51,289.94% | -22,047.17% | -3,596.67% |
| Total Other Income/Expenses | 404.43K | 2.29M | -51.02K | -535.08K |
| Income Before Tax | -29.96M | -14.67M | -10.31M | -9.53M |
| Income Before Tax Ratio | -3,142.21% | -44,368.10% | -22,156.82% | -3,810.70% |
| Income Tax Expense | 47.84K | 284.98K | -1.59M | -6.46M |
| Net Income | -30.01M | -14.96M | -8.72M | -3.07M |
| Net Income Ratio | -3,147.22% | -45,229.95% | -18,732.75% | -1,228.07% |
| EPS | -1.45 | -1.30 | -0.82 | -0.29 |
| EPS Diluted | -1.45 | -1.30 | -0.82 | -0.29 |
| Weighted Avg Shares Out | 20.73M | 11.48M | 10.57M | 10.48M |
| Weighted Avg Shares Out (Dil) | 20.73M | 11.48M | 10.57M | 10.48M |
Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Med
EDEN PRAIRIE, Minn., April 19, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that CEO Jeff Ross will...
Miromatrix Medical Inc. (MIRO) CEO Jeff Ross on Q4 2022 Results - Earnings Call Transcript
Miromatrix Medical Inc. (MIRO) CEO Jeff Ross on Q4 2022 Results - Earnings Call Transcript
12 Stocks Halted On A Circuit Breaker This Week
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.
Miromatrix to Report Fourth Quarter and Full Year 2021 Financial Results
EDEN PRAIRIE, Minn., March 17, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will...
Miromatrix Medical Inc. (MIRO) CEO Jeff Ross on Q3 2022 Results - Earnings Call Transcript
Miromatrix Medical Inc. (MIRO) CEO Jeff Ross on Q3 2022 Results - Earnings Call Transcript
Miromatrix Announces the First Successful Transplant of a Bioengineered Whole Organ in a Large Animal
Preclinical study of clinically relevant liver transplants advances the decellularization/recellularization approach, representing a key advancement in new therapies for acute and chronic liver failure patients Preclinical study of clinically relevant liver transplants advances the decellularization/recellularization approach, representing a key advancement...
Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and Kidneys
The biotechnology company working to eliminate the organ transplant waitlist outlines expansion of its clinical work, supported by IPO funds and Series C round, led by Baxter, CareDx, and DaVita The biotechnology company working to eliminate the organ transplant waitlist...
Miromatrix Medical Announces Closing of Initial Public Offering
EDEN PRAIRIE, Minn., June 28, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (Nasdaq: MIRO) ("Miromatrix"), a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives, today announced the closing...
Source: https://incomestatements.info
Category: Stock Reports